AMR Clinical Announces Leadership Transition
Kari Delahunty is appointed as the new Chief Executive Officer
Dr. William Smith will serve as Founder and Vice Chairman of the Board
AMR Clinical, a prominent integrated research site organization, recently shared pivotal news regarding its leadership structure. Dr. William B. Smith, who has been the founding CEO since the company's formal consolidation in 2017, will transition to a new role as Founder and Vice Chairman of the Board of Directors beginning December 1. Meanwhile, Kari L. Delahunty, the current Chief Operating Officer, is set to take on the responsibilities of Chief Executive Officer and join the Board on the same date.
Dr. Smith boasts an impressive tenure of over 30 years with AMR Clinical, guiding the company through substantial growth and diversification in therapeutics. He has played an essential role in the recapitalization led by Curewell Capital. David P. King, the Chairman of the Board, expressed gratitude, noting Dr. Smith's visionary leadership has been vital to AMR's success. “Dr. Smith is a trailblazer in clinical research, and we are delighted he will continue to influence the organization in a vital capacity,” added King.
Kari Delahunty’s recognition in the clinical research sector stems from her strategic leadership and operational expertise. She has held high-level roles in various global settings encompassing clinical development and innovation. Before becoming AMR Clinical's COO, Ms. Delahunty was President of Life Sciences at Shearwater Health, where she was instrumental in developing growth strategies, alongside previous experience as Senior Vice President at Syneos Health.
“Having had the privilege to lead AMR Clinical, I am confidently passing the torch to Kari, who I believe is well-equipped to guide the company towards future successes,” remarked Dr. Smith. He anticipates that under Kari’s leadership, the company will enhance its clinical research capabilities further, citing her proficiency in operational scalability as a match for AMR’s vision of sustained growth.
Upon accepting her new role, Ms. Delahunty expressed her enthusiasm. “Leading AMR Clinical during this transformative period is an incredible honor. Our commitment to delivering high-quality clinical research is unwavering, and I look forward to collaborating with our talented team to foster innovative therapeutic solutions, enhance the patient research journey, build strong customer relationships, and create value for our shareholders,” she shared.
Michael Dal Bello, a Partner at Curewell Capital and a member of AMR’s Board, acknowledged Dr. Smith’s outstanding tenure, highlighting the company’s growth under his leadership and its expansion from 15 to over 30 sites across the nation. He also congratulated Ms. Delahunty, affirming that her appointment is a significant step forward as the company seeks to explore promising new opportunities.
About AMR Clinical
AMR Clinical specializes in clinical trials across a range of medical specialties as an integrated clinical research site company. The organization is dedicated to driving medical advancements and enhancing patient outcomes. By aligning with leading healthcare providers, AMR Clinical offers innovative and efficacious research solutions. With more than 30 clinical research sites, they prioritize exceptional patient care and safety.
About Curewell Capital
Curewell is a private equity firm based in Los Angeles, focused on developing market-leading middle-market healthcare companies in North America. Leveraging decades of combined experience in healthcare investing and operations, Curewell aspires to collaborate with founders and management teams helming top-tier companies that enhance patient outcomes, optimize efficiencies, and spur innovation.
For Media Inquiries:
Michael Martin
VP of Growth, AMR Clinical
(205) 478-2585
Frequently Asked Questions
What leadership changes are taking place at AMR Clinical?
Kari Delahunty will become the new CEO, while Dr. William Smith will transition to Vice Chairman of the Board.
What has been Dr. William Smith's role at AMR Clinical?
Dr. Smith has served as the founding CEO since 2017 and has been pivotal in the company's growth and therapeutic diversification for over 30 years.
What are Kari Delahunty's qualifications?
Ms. Delahunty is known for her strategic leadership and has extensive experience in clinical development, previously holding the role of President at Shearwater Health.
What does AMR Clinical specialize in?
AMR Clinical focuses on conducting clinical trials across various medical specialties, aiming to enhance medical research and patient outcomes.
What is Curewell Capital's focus?
Curewell Capital is dedicated to building leading middle-market healthcare companies in North America, emphasizing improvements in patient outcomes and innovation.
